The Link Between COVID-19 and Obesity

Implications for NPs and PAs

Obesity clearly worsens outcomes in COVID-19 and NPs and PAs must be aware of this risk to advise patients accordingly in health promotion. Understanding the implications of diet and socioeconomic risk can improve disease outcomes.

Careful screening of patients for BMI helps modify the risk for negative outcomes of COVID-19. When clinicians make patients aware of their high BMI and the associated risks, they can provide improved access to weight management and obesity reduction strategies. Patients who have a good rapport with their health care providers might be more amenable to adopting diet and lifestyle changes, such as eating healthy, balanced meals that will improve their BMI and reduce comorbid conditions of obesity.

Clinicians can explain to patients how they can incorporate more physical activity into their daily routines. Ask patients what small changes they can make to introduce exercise into their daily schedule. Taking the stairs instead of an elevator or escalator, finding ways to sit down less and move around more, or reducing screen time are some simple suggestions. Instead of merely recommending changes or providing resources for patients to follow up with on their own, NPs and PAs should include patients in the planning process so they feel more ownership of the changes.

Clinicians can refer patients to health coaches and dietitians or nutritionists to ensure that they follow through on the recommended changes. Practicing NPs and PAs should support all patients with lifestyle modifications for weight management to protect against physiological imbalances that favor inflammation, oxidative stress, endothelial dysfunction, and immune dysregulation. When clinically indicated, patients should be referred for weight-loss pharmacotherapy or bariatric surgery.

Although more studies are needed on this topic, safeguarding patients with obesity in this health risk is pivotal during the COVID-19 pandemic. Accurate information and education are key for patients with obesity to stay safe and healthy, and NPs and PAs play an important role in patient education. When clinicians communicate effectively with their patients and help them implement a plan for modifying unhealthy behaviors and lowering their BMI, they help reduce devastating COVID-19 complications.

Kristene Diggins, DNP, MBA, FAANP, CNE, NEA-BC, DCC, is a doctorate-prepared NP with 15 years of experience as a family NP, in both primary and geriatric care. In addition, Kristene is certified as nurse educator and administrator. She served as the National Manager of Professional Practice for 4 years with Minuteclinic, supporting nurse practitioners in their career development. Kristene works as adjunct faculty for University of Phoenix as well as Chamberlain University and Liberty University. Kristene and her husband live in Charlotte, NC.


1. Kambhampati AK, O’Halloran AC, Whitaker M, et al. COVID-19-associated hospitalizations among health care personnel – COVID-NET, 13 States, March 1-May 31, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(43):1576-1583. doi:10.15585/mmwr.mm6943e3.

2. World Obesity Federation. COVID-19 and Obesity: The 2021 Atlas. March 20201. Accessed March 8, 2021.

3. Adult obesity facts. Centers for Disease Control and Prevention. Updated February 11, 2021. Accessed February 24, 2021.

4. Ryan DH, Ravussin E, Heymsfield S. COVID 19 and the patient with obesity – The editors speak out. Obesity (Silver Spring). 2020;28(5):847. doi:10.1002/oby.22808

5. Dietz W, Santos-Burgoa C. Obesity and its implications for COVID-19 mortality. Obesity (Silver Spring). 2020;28(6):1005. doi:10.1002/oby.22818

6. Kassir R. Risk of COVID-19 for patients with obesity. Obes Rev. 2020;21(6):e13034.

7. Malavazos AE, Corsi Romanelli MM, Bandera F, Iacobellis G. Targeting the adipose tissue in COVID-19. Obesity (Silver Spring). 2020;28(7):1178-1179. doi:10.1002/oby.22844

8. Muscogiuri G, Pugliese G, Barrea L, Savastano S, Colao A. Commentary: Obesity: the “Achilles heel” for COVID-19? Metabolism. 2020;108:154251. doi:10.1016/j.metabol.2020.154251

9. Kalligeros M, Shehadeh F, Mylona EK, et al. Association of obesity with disease severity among patients with coronavirus disease 2019. Obesity (Silver Spring). 2020;28(7):1200-1204. doi:10.1002/oby.22859

10. Yang J, Ma Z, Lei Y. A meta-analysis of the association between obesity and COVID-19. Epidemiol Infect. 2020 Dec 22;149:e11. doi:10.1017/S0950268820003027

11. Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J Physiol Endocrinol Metab. 2020;318(5):E736-E741. doi:10.1152/ajpendo.00124.2020

12. Lighter J, Phillips M, Hochman S, et al. Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission. Clin Infect Dis. 2020;71(15):896-897. doi:10.1093/cid/ciaa415

13. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol. 2020;215:108427. doi:10.1016/j.clim.2020.108427

14. Spagnolo P, Balestro E, Aliberti S, et al. Pulmonary fibrosis secondary to COVID-19: a call to arms? Lancet Respir Med. 2020;8(8):750-752. doi:10.1016/S2213-2600(20)30222-8

15. Cure E, Cumhur Cure M. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic. Diabetes Metab Syndr. 2020;14(4):349-350. doi:10.1016/j.dsx.2020.04.019

16. Al-Ani F, Chehade S, Lazo-Langner A. Thrombosis risk associated with COVID-19 infection. A scoping review. Thromb Res. 2020;192:152-160. doi:10.1016/j.thromres.2020.05.039

17. Kruglikov IL, Scherer PE. The role of adipocytes and adipocyte-like cells in the severity of COVID-19 infections. Obesity (Silver Spring). 2020;28(7):1187-1190. doi:10.1002/oby.22856

18. Ryan PM, Caplice NM. Is adipose tissue a reservoir for viral spread, immune activation, and cytokine amplification in coronavirus disease 2019?. Obesity (Silver Spring). 2020;28(7):1191-1194. doi:10.1002/oby.22843

19. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85-97. doi:10.1038/nri2921

20. Garvin MR, Alvarez C, Miller JI, et al. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. Elife. 2020;9:e59177. doi:10.7554/eLife.59177.

21. van de Veerdonk FL, Netea MG, van Deuren M, et al. Kinins and cytokines in COVID-19: a comprehensive pathophysiological approach. Preprints. 2020, 2020040023 (doi: 10.20944/preprints202004.0023.v1

22. van de Veerdonk FL, Kouijzer IJE, de Nooijer AH, van der Hoeven HG, Maas C, Netea MG, Brüggemann RJM. Outcomes associated with use of a kinin B2 receptor antagonist among patients with COVID-19. JAMA Netw Open. 2020;3(8):e2017708. doi:10.1001/jamanetworkopen.2020.17708

23. Severin R, Arena R, Lavie CJ, Bond S, Phillips SA. Respiratory muscle performance screening for infectious disease management following COVID-19: A highly pressurized situation. Am J Med. 2020;133(9):1025-1032. doi:10.1016/j.amjmed.2020.04.003

24. Caussy C, Wallet F, Laville M, Disse E. Obesity is associated with severe forms of COVID-19. Obesity (Silver Spring). 2020;28(7):1175. doi:10.1002/oby.22842

25. Huang JF, Wang XB, Zheng KI, et al. Letter to the editor: Obesity hypoventilation syndrome and severe COVID-19. Metabolism. 2020;108:154249. doi:10.1016/j.metabol.2020.154249

26. McLaren L. Socioeconomic status and obesity. Epidemiol Rev. 2007;29:29-48. doi:10.1093/epirev/mxm001

27. Shah M, Sachdeva M, Dodiuk-Gad RP. COVID-19 and racial disparities. J Am Acad Dermatol. 2020;83(1):e35. doi:10.1016/j.jaad.2020.04.046

28. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052-2059. doi:10.1001/jama.2020.6775

29. Abou-Arab O, Huette P, Berna P, Mahjoub Y. Tracheal trauma after difficult airway management in morbidly obese patients with COVID-19. Br J Anaesth. 2020;125(1):e168-e170. doi:10.1016/j.bja.2020.04.004

30. Luzi L, Radaelli MG. Influenza and obesity: its odd relationship and the lessons for COVID-19 pandemic. Acta Diabetol. 2020;57(6):759-764. doi:10.1007/s00592-020-01522-8

This article originally appeared on Clinical Advisor